Six MA Companies Named to Fierce 15
Six of the companies named to this year’s Fierce 15 list are based in Massachusetts, continuing the pattern of Massachusetts’ strength on the national list.
The Fierce 15 is the hotly anticipated annual award that recognizes the 15 most promising private biotech companies in the world, presented by FierceBiotech, the biotech industry’s daily monitor. The Fierce 15 celebrates the spirit of being "fierce," championing innovation and creativity, even in the face of intense competition.
“With six Commonwealth innovators included, Massachusetts has the largest representation on this year’s Fierce 15 list,” said Robert K. Coughlin, President and CEO of MassBio, which represents more than 620 biotech companies and other industry organizations. “These companies represent the next generation of our industry and are great examples of the Commonwealth’s position as a research and development hub. We congratulate this year’s winners and look forward to their continued success.”
The Massachusetts companies represented on this year’s list are:
Acetylon Pharmaceuticals (Boston)
Acetylon Pharmaceuticals, Inc s focused on development of safe, selective inhibitors of histone deacetylases (HDACs) active in the treatment of cancer, neurodegeneration, and other life-threatening diseases.
Jounce Therapeutics (Cambridge)
Jounce Therapeutics is focused on the discovery and development of first-in-class cancer immunotherapies.
Kala Pharmaceuticals (Waltham)
Kala Pharmaceuticals is developing innovative medicines that have the unprecedented ability to rapidly and effectively penetrate mucosal barriers resulting in superior therapeutic efficacy and transformative treatment outcomes for patients
Moderna Therapeutics (Cambridge)
Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted.
Nimbus Discovery (Cambridge)
Nimbus Discovery harnesses cutting-edge computational technologies to uncover breakthroughs in small molecule pharmacology.
Visterra discovers and develops novel drugs utilizing its proprietary platform based on the atomic interaction network analyses of proteins
The full Fierce 15 list is available at www.fiercebiotech.com.